# 510(k) Summary

This 510(k) Summary information is supplied in accordance with the requirements of SMDA 1990 and 21 CFR 807.92.

The assigned 510 (k) number is K133652

Date: April 28, 2014

# Submitted by:

Wallac Oy, a subsidiary of PerkinElmer Inc. 940 Winter Street   
Waltham, MA 02451

Wallac Oy Mustionkatu 6 Turku Finland 20750

# Submission Contact Person:

Primary:

Jeanette Schier-Pugsley   
Director, Regulatory and Clinical Affairs   
Tel: 781-663-6025   
Fax: 781-663-5969

Trade Name: GSP Neonatal Total Galactose kit (3309-001U)

Common Name: Regulation:

Galactose test system 21 CFR 862.1310

Classification Name:

# Classification:

I, Reserved

# Panel:

75 Clinical Chemistry

# Product Code:

Predicate device:

Neonatal Total Galactose kit [K071649]; Wallac Oy

# Device Description:

The GSP Neonatal Total Galactose kit contains sufficient reagents to perform 1152 assays. The GSP Neonatal Total Galactose test system measures total galactose, i.e. both galactose and galactose-1-phosphate, using a fluorescent galactose oxidase method. The fluorescence is measured using an excitation wavelength of ${ 5 0 5 } \mathrm { n m }$ and an emission wavelength of $5 8 0 \mathrm { n m }$ .

The kit contains the following components:

Calibrators have been prepared from human red blood cells enriched with galactose, and with ProClin 300 as preservative. The hematocrit value is $50 \%$ to correspond to a hematocrit of a newborn.The calibrators have been calibrated against primary calibrators gravimetrically prepared using a U.S. Pharmacopeia Reference Standard Preparation for galactose.

Controls have been prepared from human blood enriched with galactose and galactose-1- phosphate, and with ProClin 300 as preservative. Prior to dispensing the blood onto the filter paper, the hematocrit value  blood usd in the controls preparation is adjusted to $50 \text{‰}$ to correspond to a hematocrit of a newborn. The low control is approximately 4.0 mg/dL and the high control approximately $1 2 { \mathrm { m g / d L } }$ .

All human source materials used in the preparation of kit components were tested and found to be non-reactive for the presence of HBsAg, anti-HIV 1 and 2, and HCV by FDA approved methods.

Neonatal Total Galactose Assay Reagent 1  3 lyophilized vials Neonatal Total Galactose Assay Reagent 2  3 lyophilized vials Neonatal Total Galactose Assay Buffer  3 bottles, $4 0 ~ \mathrm { m l }$ EPY Neonatal Total Galactose Assay Reconstitution Solution - 1 bottle, 20 ml Neonatal Extraction Solution - 1 bottle, $6 0 ~ \mathrm { m l }$

# Intended Use:

The GSP Neonatal Total Galactose kit is intended for the quantitative determination of total galactose (galactose and galactose-1-phosphate) concentrations in blood specimens dried on $\mathbf { G S P } ^ { \mathfrak { B } }$ instrument.

# Comparison Chart:

Comparison of the GSP Neonatal Total Galactose device with its predicate:

<table><tr><td rowspan=1 colspan=3>GSP Neonatal Total Galactose kit</td></tr><tr><td rowspan=1 colspan=1>Characteristics</td><td rowspan=1 colspan=1>Proposed Device</td><td rowspan=1 colspan=1>Predicate (K071649)</td></tr><tr><td rowspan=1 colspan=1>IntendedUse/Indications forUse</td><td rowspan=1 colspan=1>The GSP Neonatal TotalGalactose kit is intended for thequantitative determination of totalgalactose (galactose andgalactose-1-phosphate)concentrations in blood specimensdried on filter paper as an aid inscreening newborns forgalactosemia using the GSP®instrument.</td><td rowspan=1 colspan=1>This kit is intended for thequantitative determination of totalgalactose (galactoseand galactose-1-phosphate)concentrations in blood specimensdried on filterpaper as an aid in screeningnewborns for galactosemia.</td></tr><tr><td rowspan=1 colspan=1>Test Methodology</td><td rowspan=1 colspan=1>Enzymatic assay</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Detection Method</td><td rowspan=1 colspan=1>Fluorescence - measured at 505nm and 580 nm wavelengths</td><td rowspan=1 colspan=1>Fluorescence - measured at 340 nmand 405 nm wavelengths</td></tr><tr><td rowspan=1 colspan=1>InstrumentPlatform</td><td rowspan=1 colspan=1>GSP instrument, automated(K090846)</td><td rowspan=1 colspan=1>Fluorometer, manual</td></tr><tr><td rowspan=1 colspan=1>Sample Type</td><td rowspan=1 colspan=1>Dried blood spot</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Reportable Range</td><td rowspan=1 colspan=1>1.15- 50 mg/dL</td><td rowspan=1 colspan=1>1.3 - 40 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Lower Limits ofMeasure</td><td rowspan=1 colspan=1>LoB = 0.34 mg/dLLoD = 0.97 mg/dLLoQ = 1.15 mg/dL</td><td rowspan=1 colspan=1>LoB = 0.7 mg/dLLoD = 1.3 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Calibrators</td><td rowspan=1 colspan=1>A - 0.5 mg/dLB - 2.5 mg/dLC - 5.0 mg/dLD - 10.0 mg/dLE - 20 mg/dLF - 50 mg/dL</td><td rowspan=1 colspan=1>A - 0 mg/dLB - 1.5 mg/dLC - 4.0 mg/dLD - 9.0 mg/dLE - 18 mg/dLF - 40 mg/dL</td></tr></table>

# Summary of Non-Clinical Studies:

The variation of the GSP Neonatal Total Galactose assay was determined using dried blood spot samples, 3 kit lots, and 3 GSP instruments. The study was performed in 27 runs over 21 days, each run consisting of 2 plates with 4 replicates per sample. Total number of measurements was 216 per each of seven samples. Total variation ranged from 9.3 to $1 4 . 1 \ \% \mathrm { C V }$ .

The Limi  Blank (LoB)or tal galacis $0 . 3 4 ~ \mathrm { m g / d L }$ , defined as the $9 5 ^ { \mathrm { t h } }$ percentile of a distribution of blank samples $\mathbf { \Phi } ( \mathbf { n } = 1 5 0 ^ { \circ } )$ . The Limit of Detection (LoD) is $\mathrm { 0 . 9 7 \ m g / d L }$ based on 216 determinations of 4 low level samples. The Limit of Quantitation (LoQ) is $1 . 1 5 \mathrm { m g / d L }$ , defined as the lowest concentration with a total CV equal to or less than $20 \%$ .

For the GSP Neonatal Total Galactose kit, the assay has been demonstrated to be linear throughout the measuring range (from $1 . 1 5 \mathrm { m g / d L }$ to ${ \mathfrak { s o m g } } / { \mathrm { d L } } )$

The recovery of galactose, galactose-1-phosphate, and both combined was determined from three contrived dried blood spot samples with an average recovery of $109 \%$ , $1 1 7 \%$ and $103 \%$ respectively.

The potentially interfering substances were added to whole blood with three total galactose concentrations (5, 10, and $1 5 ~ \mathrm { m g / d L } )$ A bias exceeding $\pm 1 5 \%$ is considered a significant interference. Acetaminophen and conjugated bilirubin were found to interfere with the assay by decreasing the measured total galactose concentration (see the tables below). Acetaminophen concentrations above $2 . 7 5 ~ \mathrm { m g / d L }$ and conjugated bilirubin concentrations above $1 6 . 6 \mathrm { m g / d L }$ EY may cause a false negative screening result for a specimen with measured total galactose concentration close to the cut-off value.

<table><tr><td rowspan=1 colspan=1>Total Galactoseconc. (mg/dL)</td><td rowspan=1 colspan=1>AcetaminophenConcentration testedmg/dL</td><td rowspan=1 colspan=1>Percent change inmeasured galactose(%)</td><td rowspan=1 colspan=1>Significantchange</td></tr><tr><td rowspan=4 colspan=1>5</td><td rowspan=1 colspan=1>1.38</td><td rowspan=1 colspan=1>-9.6</td><td rowspan=1 colspan=1>No</td></tr><tr><td rowspan=1 colspan=1>2.75</td><td rowspan=1 colspan=1>-9.3</td><td rowspan=1 colspan=1>No</td></tr><tr><td rowspan=1 colspan=1>4.13</td><td rowspan=1 colspan=1>-20.6</td><td rowspan=1 colspan=1>Yes</td></tr><tr><td rowspan=1 colspan=1>5.5</td><td rowspan=1 colspan=1>-22.4</td><td rowspan=1 colspan=1>Yes</td></tr><tr><td rowspan=4 colspan=1>10</td><td rowspan=1 colspan=1>1.38</td><td rowspan=1 colspan=1>-7.1</td><td rowspan=1 colspan=1>No</td></tr><tr><td rowspan=1 colspan=1>2.75</td><td rowspan=1 colspan=1>-11.8</td><td rowspan=1 colspan=1>No</td></tr><tr><td rowspan=1 colspan=1>4.13</td><td rowspan=1 colspan=1>-20.4</td><td rowspan=1 colspan=1>Yes</td></tr><tr><td rowspan=1 colspan=1>5.5</td><td rowspan=1 colspan=1>-21.9</td><td rowspan=1 colspan=1>Yes</td></tr><tr><td rowspan=4 colspan=1>15</td><td rowspan=1 colspan=1>1.38</td><td rowspan=1 colspan=1>-7.5</td><td rowspan=1 colspan=1>No</td></tr><tr><td rowspan=1 colspan=1>2.75</td><td rowspan=1 colspan=1>-11.6</td><td rowspan=1 colspan=1>No</td></tr><tr><td rowspan=1 colspan=1>4.13</td><td rowspan=1 colspan=1>-20.5</td><td rowspan=1 colspan=1>Yes</td></tr><tr><td rowspan=1 colspan=1>5.5</td><td rowspan=1 colspan=1>-21.8</td><td rowspan=1 colspan=1>Yes</td></tr></table>

<table><tr><td rowspan=1 colspan=1>Total Galactoseconc. (mg/dL)</td><td rowspan=1 colspan=1>Conjugated bilirubinConcentration testedmg/dL</td><td rowspan=1 colspan=1>Percent change inmeasured galactose(%)</td><td rowspan=1 colspan=1>Significantchange</td></tr><tr><td rowspan=4 colspan=1>5</td><td rowspan=1 colspan=1>8.3</td><td rowspan=1 colspan=1>-6.0</td><td rowspan=1 colspan=1>No</td></tr><tr><td rowspan=1 colspan=1>16.6</td><td rowspan=1 colspan=1>-10.3</td><td rowspan=1 colspan=1>No</td></tr><tr><td rowspan=1 colspan=1>24.9</td><td rowspan=1 colspan=1>-100</td><td rowspan=1 colspan=1>Yes</td></tr><tr><td rowspan=1 colspan=1>33.2</td><td rowspan=1 colspan=1>-100</td><td rowspan=1 colspan=1>Yes</td></tr><tr><td rowspan=4 colspan=1>10</td><td rowspan=1 colspan=1>8.3</td><td rowspan=1 colspan=1>-1.6</td><td rowspan=1 colspan=1>No</td></tr><tr><td rowspan=1 colspan=1>16.6</td><td rowspan=1 colspan=1>-2.7</td><td rowspan=1 colspan=1>No</td></tr><tr><td rowspan=1 colspan=1>24.9</td><td rowspan=1 colspan=1>-16.3</td><td rowspan=1 colspan=1>Yes</td></tr><tr><td rowspan=1 colspan=1>33.2</td><td rowspan=1 colspan=1>-99.9</td><td rowspan=1 colspan=1>Yes</td></tr><tr><td rowspan=4 colspan=1>15</td><td rowspan=1 colspan=1>8.3</td><td rowspan=1 colspan=1>5.9</td><td rowspan=1 colspan=1>No</td></tr><tr><td rowspan=1 colspan=1>16.6</td><td rowspan=1 colspan=1>9.3</td><td rowspan=1 colspan=1>No</td></tr><tr><td rowspan=1 colspan=1>24.9</td><td rowspan=1 colspan=1>4.4</td><td rowspan=1 colspan=1>No</td></tr><tr><td rowspan=1 colspan=1>33.2</td><td rowspan=1 colspan=1>-25.6</td><td rowspan=1 colspan=1>Yes</td></tr></table>

Intralipid' was found to not interfere up to added concentrations of $2 5 0 \mathrm { m g / d L }$ at 5 and $1 0 ~ \mathrm { m g / d L }$ total galactose; and up to $3 7 5 \mathrm { m g / d l }$ at $1 5 \mathrm { m g / d l }$ total galactose. When present above these amounts Intralipid may cause a false positive screening result for a specimen with measured total galactose concentration close to the cut-off value.

<table><tr><td rowspan=1 colspan=1>Total Galactoseconc. (mg/dL)</td><td rowspan=1 colspan=1>IntralipidConcentration testedmg/dL</td><td rowspan=1 colspan=1>Percent change inmeasured galactose (%)</td><td rowspan=1 colspan=1>Significantchange</td></tr><tr><td rowspan=7 colspan=1>5</td><td rowspan=1 colspan=1>125</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>No</td></tr><tr><td rowspan=1 colspan=1>250</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>No</td></tr><tr><td rowspan=1 colspan=1>375</td><td rowspan=1 colspan=1>23</td><td rowspan=1 colspan=1>Yes</td></tr><tr><td rowspan=1 colspan=1>500</td><td rowspan=1 colspan=1>33</td><td rowspan=1 colspan=1>Yes</td></tr><tr><td rowspan=1 colspan=1>750</td><td rowspan=1 colspan=1>37</td><td rowspan=1 colspan=1>Yes</td></tr><tr><td rowspan=1 colspan=1>1130</td><td rowspan=1 colspan=1>54</td><td rowspan=1 colspan=1>Yes</td></tr><tr><td rowspan=1 colspan=1>1500</td><td rowspan=1 colspan=1>77</td><td rowspan=1 colspan=1>Yes</td></tr><tr><td rowspan=7 colspan=1>10</td><td rowspan=1 colspan=1>125</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>No</td></tr><tr><td rowspan=1 colspan=1>250</td><td rowspan=1 colspan=1>13</td><td rowspan=1 colspan=1>No</td></tr><tr><td rowspan=1 colspan=1>375</td><td rowspan=1 colspan=1>19</td><td rowspan=1 colspan=1>Yes</td></tr><tr><td rowspan=1 colspan=1>500</td><td rowspan=1 colspan=1>19</td><td rowspan=1 colspan=1>Yes</td></tr><tr><td rowspan=1 colspan=1>750</td><td rowspan=1 colspan=1>30</td><td rowspan=1 colspan=1>Yes</td></tr><tr><td rowspan=1 colspan=1>1130</td><td rowspan=1 colspan=1>40</td><td rowspan=1 colspan=1>Yes</td></tr><tr><td rowspan=1 colspan=1>1500</td><td rowspan=1 colspan=1>52</td><td rowspan=1 colspan=1>Yes</td></tr><tr><td rowspan=7 colspan=1>15</td><td rowspan=1 colspan=1>125</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>No</td></tr><tr><td rowspan=1 colspan=1>250</td><td rowspan=1 colspan=1>13</td><td rowspan=1 colspan=1>No</td></tr><tr><td rowspan=1 colspan=1>375</td><td rowspan=1 colspan=1>15</td><td rowspan=1 colspan=1>No</td></tr><tr><td rowspan=1 colspan=1>500</td><td rowspan=1 colspan=1>24</td><td rowspan=1 colspan=1>Yes</td></tr><tr><td rowspan=1 colspan=1>750</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>Yes</td></tr><tr><td rowspan=1 colspan=1>1130</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>Yes</td></tr><tr><td rowspan=1 colspan=1>1500</td><td rowspan=1 colspan=1>29</td><td rowspan=1 colspan=1>Yes</td></tr></table>

In addition, hemoglobin in combination with elevated bilirubin concentration of $1 5 ~ \mathrm { m g / d L }$ was found to interfere with the assay by increasing the measured total galactose concentration (see the table below). Therefore, hemoglobin level at $1 9 8 \ \mathrm { g / L }$ and above in combination with elevated bilirubin level may cause a false positive screening result for a specimen with measured total galactose concentration close to the cut-off value .

<table><tr><td colspan="1" rowspan="1">Total Galactoseconc. (mg/dL)</td><td colspan="1" rowspan="1">HemoglobinConcentration testedg/L at Bilirubin level15 mg/dL</td><td colspan="1" rowspan="1">Percent change inmeasured galactose (%)</td><td colspan="1" rowspan="1">Significantchange</td></tr><tr><td colspan="1" rowspan="3">5</td><td colspan="1" rowspan="1">102</td><td colspan="1" rowspan="1">-0.8</td><td colspan="1" rowspan="1">No</td></tr><tr><td colspan="1" rowspan="1">198</td><td colspan="1" rowspan="1">26.3</td><td colspan="1" rowspan="1">Yes</td></tr><tr><td colspan="1" rowspan="1">217</td><td colspan="1" rowspan="1">5.1</td><td colspan="1" rowspan="1">No</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1">230</td><td colspan="1" rowspan="1">4.0</td><td colspan="1" rowspan="1">No</td></tr><tr><td colspan="1" rowspan="4">10</td><td colspan="1" rowspan="1">102</td><td colspan="1" rowspan="1">2.2</td><td colspan="1" rowspan="1">No</td></tr><tr><td colspan="1" rowspan="1">198</td><td colspan="1" rowspan="1">19.3</td><td colspan="1" rowspan="1">Yes</td></tr><tr><td colspan="1" rowspan="1">217</td><td colspan="1" rowspan="1">-11.0</td><td colspan="1" rowspan="1">No</td></tr><tr><td colspan="1" rowspan="1">230</td><td colspan="1" rowspan="1">7.1</td><td colspan="1" rowspan="1">No</td></tr><tr><td colspan="1" rowspan="3">15*</td><td colspan="1" rowspan="1">102</td><td colspan="1" rowspan="1">3.5</td><td colspan="1" rowspan="1">No</td></tr><tr><td colspan="1" rowspan="1">198</td><td colspan="1" rowspan="1">5.8</td><td colspan="1" rowspan="1">No</td></tr><tr><td colspan="1" rowspan="1">230</td><td colspan="1" rowspan="1">22.0</td><td colspan="1" rowspan="1">Yes</td></tr></table>

\*Due to insufficient blood volume during sample prparation, a hemoglobin sample at $2 1 7 \ \mathrm { g / L }$ could not be prepared at $1 5 ~ \mathrm { m g / d L }$ total galactose.

Hematocrit levels from $3 0 \%$ to $6 6 \%$ (Hemoglobin levels $1 0 2 { - } 2 3 0 \ \mathrm { g / L } $ were found not to interfere at total galactose concentrations of 5, 10 and $1 5 ~ \mathrm { m g / d L }$ .

The following substances were tested and found to not interfere with the measurement of total galactose for the concentration noted; Unconjugated bilirubin $( 2 0 \mathrm { m g / d L } )$ $\beta$ Nicotinamide adenine dinucleotide $( 1 0 0 \mu \mathrm { m o l / L } )$ , Glutathione $\left( 3 \mathrm { \ m m o l / L } \right)$ , Human Serum Albumin (30 $\mathrm { m g / m L } )$ , Ascorbate $( 6 ~ \mathrm { m g / d L } )$ , D-glucose $\mathrm { \Omega _ { \mathrm { ( 1 0 0 0 ~ m g / d L ) } } }$ , D-mannose $\mathrm { 1 0 0 \ m g / d L } )$ , D-fructose ${ \mathrm { ( 1 8 ~ m g / d L ) } }$ , Ampicillin $1 5 2 \mu \mathrm { m o l / L } )$ , and Lithium heparin $( \mathbf { 0 . 3 7 5 \ m g / m l } )$

# Summary of Internal Method Comparison and Screening Performance Studies:

The 3309-001U GSP Neonatal Total Galactose kit (y) was compared internally with the 3029- 0010 Neonatal Total Galactose kit (x) using routine screening and spiked blood spot specimens, duplicate measurements, in the range of $1 . 3 { \mathrm { - } } 4 0 \ { \mathrm { m g / d L } }$ $( 7 2 { - } 2 2 2 0 \ \mu \mathrm { m o l / L } )$ in the $3 0 2 9 - 0 0 1 0 \mathrm { k i t }$ the range in the 3309-001U kit being $1 . 1 5 \mathrm { - } 5 0 \mathrm { m g / d L }$ $( 6 4 - 2 7 7 5 \ \mu \mathrm { m o l / L }$ The correlation from weighted Deming regression was found to be: $\mathfrak { m g / d L }$ $\mathbf { y } { = } 1 . 1 6 \mathbf { x } - 0 . 4 9$ . $9 5 \%$ CI: slope (1.07; 1.26), intercept (-0.73; -0.25) $\scriptstyle ( 1 = 1 4 1$

The GSP Neonatal Total Galactose test system was designed with an adjusted calibration (shift of approximately $20 \%$ ) to better align performance with CDC Newborn Screening Quality Assurance Program control material. Therefore current Neonatal Total Galactose users will observe an increased recovery with the GSP Neonatal Total Galactose when running the same samples on both test systems.

In a study conducted at one newborn screening laboratory in the United States, the screening performance of the new and predicate device was evaluated with a total of 2320 samples (6 confirmed positive samples and 2314 routine samples). The screening performance is shown below based on 95.0 and 99.0 percentile values.

Screening performance of GSP Neonatal Total Galactose test system (95.0 percentile).   

<table><tr><td rowspan=1 colspan=1>GSP result</td><td rowspan=1 colspan=1>Manualresult</td><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Normal</td></tr><tr><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>82</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>76</td></tr><tr><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>:</td><td rowspan=1 colspan=1>45</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>45</td></tr><tr><td rowspan=1 colspan=1>:</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>47</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>47</td></tr><tr><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1>2146</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>2146</td></tr><tr><td rowspan=1 colspan=2>Total</td><td rowspan=1 colspan=1>2320</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>2314</td></tr></table>

Overall percent agreement $= ( 8 2 + 2 1 4 6 ) / 2 3 2 0 ^ { * } 1 0 0 \% = 9 6 . 0 \%$ Positive percent agreement $= ( 8 2 / 1 2 9 ) \ast 1 0 0 \% = 6 3 . 6 \%$ E Negative percent agreement $: = ( 2 1 4 6 / 2 1 9 1 ) * 1 0 0 \% = 9 7 . 9 \%$

Screening performance of GSP Neonatal Total Galactose test system (99.0 percentile).   

<table><tr><td rowspan=1 colspan=1>GSP result</td><td rowspan=1 colspan=1>Manualresult</td><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Normal</td></tr><tr><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>16</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>10</td></tr><tr><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1>14</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>14</td></tr><tr><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>14</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>14</td></tr><tr><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1>2276</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>2276</td></tr><tr><td rowspan=1 colspan=2>Total</td><td rowspan=1 colspan=1>2320</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>2314</td></tr></table>

Overall percent agreement $= ( 1 6 + 2 2 7 6 ) / 2 3 2 0 ^ { * } 1 0 0 \% = 9 8 . 8 \%$ Positive percent agreement $= ( 1 6 / 3 0 ) * 1 0 0 \% = 5 3 . 3 \%$ EY Negative percent agreement $= ( 2 2 7 6 / 2 2 9 0 ) * 1 0 0 \% = 9 9 . 4 \%$

# Substantial Equivalency:

The proposed device and predicate device utilize similar enzymatic pathway and design shown to produce equivalent screening performance in a clinical setting. Both devices are intended for use in for the quantitative determination of total galactose (galactose and galactose-1-phosphate) concentrations in blood specimens dried on filter paper as an aid in screening newborns for galactosemia

# Conclusion:

Th GS Neoatal Tol Galacse  ystdmta nalytical and c performance that supports its substantial equivalency with the predicate device, the Neonatal Total Galactose test system (K071649).

WALLAC OY. A SUBSIDIARY OF PERKIN ELMER. INC.C/O JEANETTE SCHIER-PUGSLEY  
DIRECTOR OF REGULATORY AFFAIRS  
940 WINTER STREET  
WALTHAM MA 02451

Rc: K133652 Trade/Device Name: GSP Neonatal Total Galactose Kit Regulation Number: 21 CFR 862.1310 Regulation Name: Galactose test system Regulatory Class: 1. Reserved Product Code: JIA Dated: April 14. 2014 Received: April 15. 2014

Dear Ms. Jeanette Schier-Pugsley:

We have reviewed your Section $5 1 0 ( k )$ premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28. 1976. the enactment date of the Medical Device Amendments, or to devies that have been reclassifid in accordance with the provisions of the Federal Food. Drug. and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may. therefore. market the device. subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration. listing of devices. good manufacturing practice. labeling. and prohibitions against misbranding and adulteration. Pleasc note: CDRH does not evaluate information related to contract liability warranties. We remind you, however. that device labcling must be truthful and not misleading.

If your device is classified (see above) into.cither class I (Special Controls) or class II (PMA). it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations. Title 21. Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination thal your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with al the Act's requirements. including. but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809): medical device reporting (reporting of medical device-related adverse cvents) (21 CFR 803): good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820): and if applicable. the electronic product radiation control provisions (Sections 531-542 of the Act): 21 CFR 1000- 1050.

If you desire specific advice for your device on our labeling regulations (21 CFR Parts 801 and 809), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638 2041 or (301) 796-7100 or at its Internet address   
http://wwv.fda.gov/MedicatDevices/ResourcesforYou/Industry/default.htm. Also. please note the regulation entitled. "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to   
http://wwwv.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-frce number (800) 638-204 1 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours.

# Courtney H. Lias -S

Courtney H. Lias. Ph.D.   
Director   
Division of Chemistry and Toxicology Devices Office of In Vitro Diagnosties   
and Radiological Health   
Center for Devices and Radiological Health

# Enclosure

Device Name GSP Neonatal Total Galactose kit

Indications for Use (Describe)

Te lTl l v galactosemia using the $\Game \ P \otimes$ instrument.

Yung W Chan -S

This section applies only to requirements of the Paperwork Reduction Act of 1995.

# \*DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW."

Te burn torcolltion  noation s tat vegours p nnc time to review instructions, search existing dat sources, gather and maintain the data needed and coplete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."